LTZ Therapeutics, an immunotherapy-focused biotechnology company, has entered into a strategic research collaboration with Eli Lilly and Company to develop novel myeloid engager therapeutics against selected targets for the treatment of diseases with high unmet need. The partnership was announced on July 29, 2025, combining LTZ's first-in-class Myeloid Engager Platform with Lilly's world-class expertise in research, development and commercialization.
Financial Terms and Structure
Under the terms of the agreement, LTZ will receive a double-digit million USD upfront payment and an equity investment in the company. The biotechnology company is also eligible to receive preclinical, clinical, regulatory and commercial milestone payments, in addition to tiered royalties on net sales of any resulting commercialized products.
Strategic Vision and Leadership Perspective
"We are thrilled to enter into a strategic partnership with Lilly, a global leader in immunology and oncology," said Robert Li, Founder and CEO of LTZ. "This collaboration represents a pivotal step towards our mission in harnessing the potential of myeloid biology to address diseases with high unmet need. With Lilly's expertise and global reach, we're accelerating the development of our myeloid engager programs and we're one step closer to bringing transformative therapies to the patients who need them most."
LTZ's Myeloid Engager Platform
LTZ Therapeutics is pursuing the development of novel therapies through its proprietary Myeloid Engager Platform, designed to improve clinical outcomes in patients with cancer and autoimmune diseases. The company is dedicated to developing myeloid engager immunotherapies for broad disease indications, leveraging the potential of myeloid biology to address therapeutic challenges.
Company Operations and Global Presence
LTZ maintains main operations in Redwood City, California and Shenzhen, China, with an additional team based in Heidelberg, Germany. This international presence positions the company to leverage global expertise and resources in advancing its immunotherapy programs through the collaboration with Lilly.
